Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Dec 19, 2023

SELL
$2.8 - $5.46 $75,079 - $146,404
-26,814 Reduced 12.45%
188,581 $546,000
Q1 2023

May 15, 2023

SELL
$2.8 - $5.46 $75,079 - $146,404
-26,814 Reduced 12.45%
188,581 $547,000
Q4 2022

Dec 19, 2023

BUY
$2.85 - $5.18 $613,875 - $1.12 Million
215,395 New
215,395 $706,000
Q4 2022

Feb 15, 2023

SELL
$2.85 - $5.18 $114,615 - $208,318
-40,216 Reduced 15.73%
215,395 $706,000
Q3 2022

Nov 15, 2022

BUY
$2.85 - $8.73 $330,981 - $1.01 Million
116,134 Added 83.26%
255,611 $966,000
Q2 2022

Aug 15, 2022

BUY
$4.69 - $9.84 $129,331 - $271,347
27,576 Added 24.64%
139,477 $1.09 Million
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $423,063 - $846,628
50,126 Added 81.14%
111,901 $1.04 Million
Q4 2021

Feb 15, 2022

SELL
$14.7 - $19.89 $432,900 - $585,740
-29,449 Reduced 32.28%
61,775 $974,000
Q3 2021

Nov 15, 2021

BUY
$11.99 - $17.9 $328,885 - $490,996
27,430 Added 43.0%
91,224 $1.63 Million
Q4 2020

Feb 12, 2021

SELL
$12.67 - $26.23 $291,790 - $604,076
-23,030 Reduced 26.52%
63,794 $1.25 Million
Q3 2020

Nov 16, 2020

BUY
$11.92 - $15.87 $1.03 Million - $1.38 Million
86,824 New
86,824 $1.13 Million
Q1 2020

May 13, 2020

SELL
$5.69 - $17.78 $225,779 - $705,510
-39,680 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$10.89 - $16.79 $151,534 - $233,632
13,915 Added 54.01%
39,680 $654,000
Q2 2019

Aug 12, 2019

BUY
$19.05 - $41.04 $110,928 - $238,975
5,823 Added 29.2%
25,765 $518,000
Q1 2019

May 15, 2019

BUY
$28.4 - $41.74 $112,265 - $164,998
3,953 Added 24.72%
19,942 $793,000
Q4 2018

Feb 15, 2019

BUY
$30.9 - $42.97 $494,060 - $687,047
15,989 New
15,989 $555,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Public Employees Retirement System Of Ohio Portfolio

Follow Public Employees Retirement System Of Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement System Of Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement System Of Ohio with notifications on news.